Table 2.

Current Targeted Therapies for Renal Cell Carcinoma

Median OverallMedian Progression-Free
DrugIndicationSurvival, monthsSurvival, monthsTargets
Sunitinib78,79First line26.411.0VEGFR, PDGFR, FLT3, c-KIT, CSF1R, RET
Sorafenib80Second line19.35.5VEGFR, PDGFR, RAF
Pazopanib81First and second line22.911.1VEGFR, FLT3, c-KIT, PDGFR
Everolimus82Second line14.84.0mTOR, HIF1, VEGF
Temsirolimus83First line10.93.8mTOR, HIF1, HIF2, VEGF
Axitinib84Second line21.710.1VEGFR, PDGFR, c-KIT
Bevacizumab + interferon alpha85First line18.310.2VEGF
Cabozantinib86Second line21.47.4RET, KIT, AXL, FLT3, c-MET, VEGFR
Dovitinib87Second line9.73.6FGFR, VEGFR, PDGFR
Nivolumab88,99Second line23.42.7-4.2PD-1
Lenvatinib89Second line18.47.4VEGFR, PDGFR, FGFR, RET, c-KIT
  • AXL, receptor tyrosine kinase; c-KIT, tyrosine-protein kinase; c-MET, tyrosine-protein kinase met; CSF1R, colony-stimulating factor 1 receptor; FGFR, fibroblast growth factor receptor; FLT3, fms-like tyrosine kinase 3; HGF, hepatocyte growth factor; HIF1/2, hypoxia-inducible factor 1/2; IFN-α, interferon alpha; KIT, proto-oncogene; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; PD-1, programmed death protein 1; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; RAF, rapidly accelerated fibrosarcoma; RET, proto-oncogene rearranged during transfection; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.